Travere Therapeutics (TVTX) Other Working Capital Changes (2021 - 2025)

Travere Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$1.5 million for Q2 2025.

• Quarterly Other Working Capital Changes rose 30.88% year-over-year to -$1.5 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 75.33% YoY) and the FY2025 annual result came in at -$2.8 million, up 53.97% from the prior year.
• Other Working Capital Changes was -$1.5 million for Q2 2025 at Travere Therapeutics, down from -$1.3 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.4 million in Q1 2026 and bottomed at -$3.1 million in Q2 2023.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes plunged 117.54% — and 2024, when it soared 89.98%.
• Travere Therapeutics' Other Working Capital Changes stood at -$1.9 million in 2021, then sank by 117.54% to -$4.0 million in 2022, then sank by 38.4% to -$5.6 million in 2023, then surged by 89.98% to -$559000.0 in 2024, then slumped by 162.25% to -$1.5 million in 2025.
• Business Quant data shows TVTX's Other Working Capital Changes at -$1.5 million in Q2 2025, -$1.3 million in Q1 2025, and -$559000.0 in Q4 2024.